Literature DB >> 2525403

Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma.

R Becher1, O Kloke, K Höffken, M E Scheulen, U B Wandl, H Bojar, C G Schmidt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525403      PMCID: PMC2246743          DOI: 10.1038/bjc.1989.201

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  5 in total

1.  Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma.

Authors:  E T Creagan; A J Schutt; D L Ahmann; S J Green
Journal:  Cancer Treat Rep       Date:  1982-05

2.  Gradient centrifugation analysis of steroid-hormone binding in human malignant melanoma.

Authors:  H Bojar; B Stuhldreier; R Becher; U Koldovsky; G Goerz; H Merk; W Staib
Journal:  Anticancer Res       Date:  1982 Jul-Aug       Impact factor: 2.480

3.  Estrogen and progesterone receptors and tamoxifen in malignant melanoma.

Authors:  C P Karakousis; R E Lopez; H S Bhakoo; F Rosen; R Moore; M Carlson
Journal:  Cancer Treat Rep       Date:  1980 Jun-Jul

4.  Receptor for glucocorticoids in RPMI 3460 melanoma cells.

Authors:  E F Hawkins; D Horn; F S Markland
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

5.  High incidence and characterization of glucocorticoid receptors in human malignant melanoma.

Authors:  H S Bhakoo; R J Milholland; R Lopez; C Karakousis; F Rosen
Journal:  J Natl Cancer Inst       Date:  1981-01       Impact factor: 13.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.